Navigation Links
Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI) has presented pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation (www.inflammation2007.dk) held in Copenhagen June 16-20*.

"The results strengthen the further clinical development of 57-57 for the treatment of SLE and show the possibility to reduce the use of steroids. Phase II clinical trials are planned to be initiated before year end", commented Sven Andréasson, President & CEO Active Biotech.

The new pre-clinical data presented show that 57-57, in an experimental model of the disease systemic lupus erythematosus (SLE), can replace prednisolone, an anti-inflammatory corticosteroid widely used in a broad range of different inflammatory diseases, among them SLE.

Several symptoms commonly associated with SLE, such as hematuria (blood in the urine) and glomerulonephritis (inflammation in the kidneys) could be significantly reduced when combining 57-57 and a lower dose of steroid.

Lund, June 18, 2007

Active Biotech AB (Publ)

Sven Andréasson President & CEO

About SLE and 57-57 Systematic Lupus Erythematosus (SLE) is a disease of the connective tissues that can cause inflammation and damage to the connective tissue in many different organs. The disease, which progresses in "flare-ups" interspersed with relatively symptom-free periods, primarily affects women of child-bearing age. Progress and symptoms of the disease vary widely, depending on the organs affected. Without treatment, SLE can be life-threatening. Active Biotech has decided to estimate the market conservatively at 1,000,000 patients in the US and Europe. The market potential for the SLE indication is estimated at approximately USD 6 billion.

The clinical program for the 57-57 project with the main indication SLE is proceedi ng according to plan. This study comprises patients with SLE or rheumatoid arthritis (RA). This is a multi-center study and is being conducted at three hospitals in Sweden - the Karolinska University Hospital in Stockholm, Uppsala University Hospital and Lund University Hospital, in addition to clinics in Russia. Phase II studies are planned to start during 2007.

57-57 has been given the international generic name (INN) paquinimod by the World Health Organization (WHO).

* For further information and to take part of the complete poster "Steroid Sparing Effect of Paquinimod (ABR-215757) in Disease Development of Experimental Lupus in MRLlpr/lpr Mice", please visit www.activebiotech.com .

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org. no. 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


'"/>




Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Gentiums Defibrotide Seen as Active in Multiple Myeloma
3. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
4. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
10. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
11. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... Ind. , Aug. 7, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the third quarter of 2017. ... be paid on or about October 27, 2017 to stockholders ... 22, 2017.  Future declarations of dividends are subject to approval ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas ... Worth area, is spearheading a regional charity campaign organized to provide support to Christina ... June of this year, Christina and her children returned from out of town to ...
(Date:8/18/2017)... , ... August 18, 2017 , ... Inc. magazine has ... the most prestigious ranking of the nation's fastest-growing private companies. This marks the eighth ... Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue ...
(Date:8/18/2017)... ... ... “Beyond Our Imaginations: The Infinite God”: shows the importance of God in living a ... published author, Mark Lawrence, born in Michigan, the author has lived in various communities ... man of God is that I have to be more mindful of feminine qualities ...
(Date:8/18/2017)... ... 2017 , ... “Steve the Snake”: an entertaining and moral-based short story about ... published author, Harold Flash Haskins Jr., a husband, father and grandfather who served as ... “I write moral-based short stories for children and teens. My goal is to teach ...
(Date:8/17/2017)... Wilmington, Delaware (PRWEB) , ... August 17, 2017 , ... ... bedside, well actually, stretcher side nurse, she took with her a dream to make ... science of healthcare. Specifically, ensuring communication skills were integrated into healthcare provider education. ...
Breaking Medicine News(10 mins):